Chronic spontaneous (idiopathic) urticaria in combination with delayed urticaria from skin pressure

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Chronic urticaria (CU) is a condition that occurs due to known and unknown causes, in which wheals, each of which exists for no more than 24 hours, appear daily or almost daily for > 6 weeks. CU is classified as induced, when there is a direct cause-and-effect correlation between the impact of certain triggers and the appearance of urticaria, and spontaneous, when specific triggers are unknown. The first line of therapy for chronic spontaneous (idiopathic) urticaria are second-generation H1-antihistamines, which effectively block all the effects of histamine, realized through H1-receptors, and have an additional anti-inflammatory effect. Article describes a clinical observation of successful symptom control in a patient with chronic spontaneous (idiopathic) urticaria in combination with delayed pressure urticaria using the second-generation H1-antihistamine fexofenadine medication.

全文:

受限制的访问

作者简介

Laura Bolieva

North Ossetian State Medical Academy of the Ministry of Healthcare of Russia

编辑信件的主要联系方式.
Email: bolievalz@mail.ru
ORCID iD: 0000-0002-1820-7726
SPIN 代码: 1811-9351

MD, Dr. Sci. (Medicine), professor, head of the Department of pharmacology with clinical pharmacology

俄罗斯联邦, Vladikavkaz

参考

  1. Клинические рекомендации. Крапивница. Российская ассоциация аллергологов и клинических иммунологов, Союз педиатров России, общероссийская общественная организация «Российское общество дерматовенерологов и косметологов». Рубрикатор клинических рекомендаций Минздрава России. 2023. ID: 264_2. Доступ: https://cr.minzdrav.gov.ru/preview-cr/264_2 (дата обращения – 24.04.2025) [Clinical recommendations. Urticaria. Russian Association of Allergologists and Clinical Immunologists, Union of Pediatricians of Russia, Russian Society of Dermatovenerologists and Cosmetologists. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2023. ID: 264_2. URL: https://cr.minzdrav.gov.ru/preview-cr/264_2 (date of access – 24.04.2025) (In Russ.)].
  2. Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J et al. Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy. 2011;66(3):317–30. PMID: 21083565. https://doi.org/10.1111/j.1398-9995.2010.02496.x
  3. Moestrup K, Ghazanfar MN, Thomsen SF. Patient-reported outcomes (PROs) in chronic urticaria. Int J Dermatol. 2017;56(12):1342–48. PMID: 28567776. https://doi.org/10.1111/ijd.13668
  4. Свечникова Е.В., Жуфина С.Е. Современные представления о патогенезе хронической крапивницы. Эффективные методы лечения. Фарматека. 2023;30(9–10):198–202. [Svechnikova EV, Zhufina SE. Modern concepts of the pathogenesis of chronic urticaria. Effective treatment methods. Farmateka. 2023;30(9–10):198–202 (In Russ.)]. EDN: GQCQNS. https://dx.doi.org/10.18565/pharmateca.2023.9-10.198-202
  5. Elieh-Ali-Komi D, Metz M, Kolkhir P, Kocatürk E, Scheffel J, Frischbutter S et al. Chronic urticaria and the pathogenic role of mast cells. Allergol Int. 2023;72(3):359–68. PMID: 37210251. https://doi.org/10.1016/j.alit.2023.05.003
  6. Greenberger PA. Chronic urticaria: New management options. World Allergy Organ J. 2014;7(1):31. PMID: 25383135. PMCID: PMC4223736. https://doi. org/10.1186/1939-4551-7-31
  7. Pozderac I, Lugović-Mihic L, Artuković M, Stipić-Marković A, Kuna M, Ferček I. Chronic inducible urticaria: Classification and prominent features of physical and non-physical types. Acta Dermatovenerol Alp Pannonica Adriat. 2020;29(3):141–48. PMID: 32975301. https://doi.org/10.15570/actaapa.2020.29
  8. Maurer M, Staubach P, Raap U, Richter-Huhn G, Bauer A, Ruëff F et al. H1-antihistamine-refractory chronic spontaneous urticaria: It’s worse than we thought – first results of the multicenter real-life AWARE study. Clin Exp Allergy. 2017;47(5):684–92. PMID: 28160338. https://doi.org/10.1111/cea.12900
  9. Zuberbier T, Latiff AHA, Abuzakouk M, Aquilina S, Asero R, Baker D et al. The international EAACI/GA(2)LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734–66. PMID: 34536239. https://doi.org/10.1111/all.15090
  10. Kovalkova E, Fomina D, Borzova E, Maltseva N, Chernov A, Serdoteckova S et al. Comorbid inducible urticaria is linked to non-autoimmune chronic spontaneous urticaria: CURE insights. J Allergy Clin Immunol Pract. 2024;12(2):482–90.e1. PMID: 38008357. https://doi.org/10.1016/j.jaip.2023.11.029
  11. Maurer M, Abuzakouk M, Bérard F, Canonica W, Elberink HO, Giménez-Arnau A et al. The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU. Allergy. 2017;72(12):2005–16. PMID: 28543019. PMCID: PMC5724512. https://doi.org/10.1111/all.13209
  12. Atefi N, Rahimi M, Peyghambari S, Ghourchian S. Psychological status in patients with chronic urticaria. Med J Islam Repub Iran. 2011;25(4):200–4.
  13. Jauregui I, Ferrer M, Montoro J, Dávila I, Bartra J, del Cuvillo A et al. Antihistamines in the treatment of chronic urticaria. J Investig Allergol Clin Immunol. 2007;17(Suppl 2):41–52. PMID: 18228682.
  14. Simons FER, Silver NA, Gu X, Simons KJ. Clinical pharmacology of H1-antihistamines in the skin. J Allergy Clin Immunol. 2002;110(5):777–83. PMID: 12417888. https://doi.org/10.1067/mai.2002.129123
  15. Емельянов А.В., Кочергин Н.Г., Горячкина Л.А. К 100-летию открытия гистамина. История и современные подходы к клиническому применению антигистаминных препаратов. Клиническая дерматология и венерология. 2010;8(4):62–70. [Emel’yanov AV, Kochergin NG, Goryachkina LA. The history and modern approaches to clinical use of antihistaminic drugs. Klinicheskaya dermatologiya i venerologiya = Russian Journal of Clinical Dermatology and Venereology. 2010;8(4):62–70 (In Russ.)]. EDN: QAAMXN.
  16. Леонова М.В. Современные антигистаминные препараты: выбор в изобилии предложений. Фарматека. 2011;(10):26–32. [Leonova MV. Modern antihistamines: A choice in abundance of offers. Farmateka. 2011;(10):26–32 (In Russ.)]. EDN: OFUGHH.
  17. Государственный реестр лекарственных средств Минздрава России. Инструкция по медицинскому применению препарата Фексадин®. РУ: ЛП-№(003701)-(РГ-RU) от 15.11.2023. Доступ: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=368a67ab-988d-4a10-98f5-0df6e30ad663 (дата обращения – 24.04.2025). [State register of medicines of the Ministry of Healthcare of Russia. Instructions for medical use of the drug Fexadin. Registration certificate: ЛП-№(003701)-(РГ-RU) from 11/15/2023. URL: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=368a67ab-988d-4a10-98f5-0df6e30ad663 (date of access – 24.04.2025) (In Russ.)].
  18. Пономарева А.В., Некрасова Е.Е., Разваляева О.В. Сравнительная эффективность антиаллергической терапии хронической крапивницы у взрослых. Волгоградский научно-медицинский журнал. 2012;(4):19–21. [Ponomareva AV, Nekrasova EE, Razvalyaeva OV. Comparative effectiveness of antiallergic therapy of chronic urticaria in adults. Volgogradskiy nauchno-meditsinskiy zhurnal = Volgograd Scientific Medical Journal. 2012;(4):19–21 (In Russ.)]. EDN: SJTBVL.
  19. Vena GA, Cassano N, Filieri M, Filotico R, D’Argento V, Coviello C. Fexofenadine in chronic idiopathic urticaria: A clinical and immunohistochemical evaluation. Int J Immunopathol Pharmacol. 2002;15(3):217–24. PMID: 12575922. https://doi.org/10.1177/039463200201500308
  20. Ansotegui IJ, Bernstein JA, Canonica GW, Gonzalez-Diaz SN, Martin BL, Morais-Almeida M et al. Insights into urticaria in pediatric and adult populations and its management with fexofenadine hydrochloride. Allergy Asthma Clin Immunol. 2022;18(1):41. PMID: 35562767. PMCID: PMC9103601. https://doi.org/10.1186/s13223- 022-00677-z
  21. Kaplan AP, Spector SL, Meeves S, Liao Y, Varghese ST, Georges G. Once-daily fexofenadine treatment for chronic idiopathic urticaria: A multicenter, randomized, double-blind, placebo-controlled study. Ann Allergy Asthma Immunol. 2005;94(6):662–69. PMID: 15984599. https://doi.org/10.1016/S1081-1206(10)61325-7
  22. Rosenfeld GC, Loose DS. Pharmacology. 6th ed. Lippincott Williams & Wilkins. 2013; 389 р. ISBN-10: 9351290751. ISBN-13: 978-9351290759.
  23. Naclerio RM, Ansotegui IJ, Canonica GW, Rouadi P, Zhang L, Murrieta-Aguttes M. Twenty-five years: The fexofenadine clinical experience. World Allergy Organ J. 2024;17(9):100950. PMID: 39252789. PMCID: PMC11382105. http://doi.org/10.1016/j.waojou.2024.100950
  24. Ненашева H.М. Антигистаминные препараты в клинической практике: Клиническое руководство для врачей. М.: Медконгресс. 2024; 96 с. [Nenasheva NM. Antihistamines in clinical practice: A clinical guide for physicians. Moscow: Medkongress. 2024; 96 pp. (In Russ.)]. ISBN: 978-5-6052237-5-7.
  25. Новиков А.Г., Логунова З.В., Потекаев Н.Н. Фексофенадин в терапии хронической идиопатической крапивницы. Клиническая дерматология и венерология. 2003;1(2):53–54. [Novikov AG, Logunova ZV, Potekaev NN. Fexofenadine in the treatment of chronic idiopathic urticaria. Klinicheskaya dermatologiya i venerologiya = Russian Journal of Clinical Dermatology and Venereology. 2003;1(2):53–54 (In Russ.)].
  26. Карачева Ю.В., Шестерня О.В. Опыт применения фексадина при аллергических дерматозах. Сибирское медицинское обозрение. 2003;(4):64–65. [Karacheva YuV, Shesternya OV. Experience of using fexadine in allergic dermatoses. Sibirskoe meditsinskoe obozreniye = Siberian Medical Review. 2003;(4):64–65 (In Russ.)]. EDN: KPANXN.

补充文件

附件文件
动作
1. JATS XML
下载
2. 1. The effect of chronic urticaria on the quality of life, sleep and daily activities according to the EQ-5D-3L questionnaire [14]

下载 (148KB)
索引源数据
3. Fig. 2. Algorithm of therapy for a patient with chronic urticaria [1]

下载 (168KB)
索引源数据

版权所有 © Bionika Media, 2025